Sabinsa's Curcumin C3 Complex® And BioPerine® Combination Used In Published Study On Metabolic Syndrome

Another significant study on the combination of Curcumin C3 Complex® and BioPerine®, Lipid-modifying effects of adjunctive therapy with curcuminoids–piperine combination in patients with metabolic syndrome: Results of a randomized controlled trial, by researchers at University of Medical Sciences, Mashhad, Iran, has been published in Complementary Therapies in Medicine 2014; 22(5): 851-857.

Curcumin C3 Complex

A randomized, double-blind, placebo-controlled, parallel group clinical trial was conducted with 117 patients for 8 weeks. Patients received either Curcumin C3 Complex® plus BioPerine® combination or matched placebo capsules twice daily for 8 weeks. Complete lipid profile including LDL-C, non-HDL-C, Total Cholesterol, Triglyceride and Lp(a) were determined at the baseline and at end of the trial.

The study results showed significantly greater effect of Curcuminoids in reducing the serum concentrations of LDL-C, non-HDL-C, total cholesterol, triglycerides and Lp(a) in comparison to the placebo group. Serum HDL-C concentration was elevated significantly in the Curcuminoids group. Serum sdLDL levels were comparable in both groups at baseline and at the end of the trial. Overall effects of Curcuminoids on triglycerides, non-HDL-C, total cholesterol and Lp(a) remained significant after adjustment for baseline BMI. Curcumin C3 Complex® plus BioPerine® combination was well tolerated in patients with metabolic syndrome.

This study is the first trial investigating the efficacy and safety of adjunctive therapy with Curcuminoids-Piperine combination in patients with metabolic syndrome, receiving standard treatment. The results of the trial supported the effectiveness of the adjunctive therapy with significant decrease in serum concentration LDL-C, non-HDL-C, total cholesterol, triglyceride, Lp(a) and elevation in serum concentration of HDL-C in patients in comparison to the standard therapy alone. The present study also encouraged the efficacy of use of co-administering BioPerine® as a bioavailability enhancer.

"This research indicates additional benefits of Curcumin beyond inflammation, giving increased value to C3 Complex as the body of science grows" said Shaheen Majeed, Sabinsa Marketing Director. "And once again the C3 Complex and BioPerine combination has been shown to be a safe and effective supplement blend that can help keep people healthy."

Sabinsa's Curcumin C3 Complex® has been subject of over 72 research papers including 34 clinical studies published in peer reviewed journals. The combination of Curcumin C3 Complex® and BioPerine® has been studied in several independent clinical trials, including one published by Tufts University validating its safety and quality of ingredients and another on osteoarthritis from University of Medical Sciences, Mashhad, Iran.

    HEADQUARTERS

  • Sabinsa Corporation
    20 Lake Drive
    East Windsor
    NJ 08520, USA

  • +1 732 777 1111
  • +1 732 777 1443
  • info@sabinsa.com

CERTIFICATES

Certificate Logos Certificate Logos
Certificate Logos Certificate Logos

CONTACT US

Disclaimer

Please note that this website and information provided herein is not for final consumers of a finished food, beverage, dietary supplement product or cosmetic product, as the information contained herein does not refer to finished products for consumers.

The information provided on the website is intended only for producers of finished food, beverage, dietary supplement and cosmetic product.

The statements related to ingredients on the website, have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

The website and information herein are available in various countries across the world, and hence statements or product information including its classification may not be applicable in your country.

Information and statements provided on the website, shall not be construed as license to practice, or recommendations to infringe, any patents or other intellectual property rights of Sabinsa and others.

By browsing further, You understand the above terms.